We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
BASF licenses CRISPR-Cpf1 from the Broad Institute of MIT and Harvard
News

BASF licenses CRISPR-Cpf1 from the Broad Institute of MIT and Harvard

BASF licenses CRISPR-Cpf1 from the Broad Institute of MIT and Harvard
News

BASF licenses CRISPR-Cpf1 from the Broad Institute of MIT and Harvard

BASF technicians in a white biotechnology research lab in Germany are working with microorganisms to produce enzymes. Credit: BASF
Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "BASF licenses CRISPR-Cpf1 from the Broad Institute of MIT and Harvard"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

The chemical company BASF has attained a global, non-exclusive licensing agreement with the Broad Institute of MIT and Harvard for the use of CRISPR-Cpf1 genome editing technology to improve products in agricultural and industrial microbiology applications.


CRISPR-Cpf1 has demonstrated distinct advantages for certain applications over CRISPR-Cas9, which BASF has previously licensed from the Broad Institute. By adding CRISPR-Cpf1 to its portfolio, BASF has the flexibility to choose the right tool for specific applications. Access to both technologies will also help to accelerate the development of new agricultural and industrial microbiology products.


"Genome editing tools represent the next step in molecular biology innovation," said Peter Eckes, President of BASF Bioscience Research. "The addition of CRISPR-Cpf1 greatly expands our technological capabilities in modern agriculture and industrial solutions and we are eager to see how these technologies will improve multiple products in these areas."


"This technology represents a transformative application of genome editing for the research community," said Issi Rozen, Chief Business Officer of the Broad Institute. "CRISPR-Cpf1 can directly benefit advanced research across many industries including human health and agriculture. We are proud to partner with stakeholders throughout the biomedical and agriculture community to help deliver responsible solutions for our planet."

This article has been republished from materials provided by BASF. Note: material may have been edited for length and content. For further information, please contact the cited source.

Advertisement